company background image
EVAX logo

Evaxion NasdaqCM:EVAX Stock Report

Last Price

US$1.74

Market Cap

US$11.0m

7D

16.9%

1Y

-90.6%

Updated

17 May, 2025

Data

Company Financials +

EVAX Stock Overview

Evaxion Biotech A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. More details

EVAX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Evaxion A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Evaxion
Historical stock prices
Current Share PriceUS$1.74
52 Week HighUS$20.81
52 Week LowUS$1.20
Beta-0.23
1 Month Change33.03%
3 Month Change-30.06%
1 Year Change-90.64%
3 Year Change-98.13%
5 Year Changen/a
Change since IPO-99.65%

Recent News & Updates

Recent updates

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Mar 31

Evaxion Biotech names Per Norlén as CEO

Oct 05

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Aug 10

Evaxion Biotech announces new CEO as Lars Wegner resigns

Aug 02

Shareholder Returns

EVAXUS BiotechsUS Market
7D16.9%3.7%5.3%
1Y-90.6%-14.2%11.9%

Return vs Industry: EVAX underperformed the US Biotechs industry which returned -14.2% over the past year.

Return vs Market: EVAX underperformed the US Market which returned 11.9% over the past year.

Price Volatility

Is EVAX's price volatile compared to industry and market?
EVAX volatility
EVAX Average Weekly Movement10.0%
Biotechs Industry Average Movement11.9%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market4.1%

Stable Share Price: EVAX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: EVAX's weekly volatility has decreased from 19% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200846Christian Kanstrupevaxion.ai

Evaxion Biotech A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus.

Evaxion A/S Fundamentals Summary

How do Evaxion's earnings and revenue compare to its market cap?
EVAX fundamental statistics
Market capUS$11.00m
Earnings (TTM)-US$10.57m
Revenue (TTM)US$3.34m

3.3x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVAX income statement (TTM)
RevenueUS$3.34m
Cost of RevenueUS$0
Gross ProfitUS$3.34m
Other ExpensesUS$13.91m
Earnings-US$10.57m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.67
Gross Margin100.00%
Net Profit Margin-316.00%
Debt/Equity Ratio-494.4%

How did EVAX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/17 05:14
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evaxion A/S is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
Thomas FlatenLake Street Capital Markets, LLC
Kevin DeGeeterOppenheimer & Co. Inc.